GE HealthCare has announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging, or MRI, contrast agent. The results, which will be used to support ongoing clinical development, concluded that in a first-in-human study, this manganese-based contrast agent was well tolerated with no serious adverse events, dose-limiting toxicities or clinically relevant findings reported, according to an abstract presented at the 2024 bi-annual Contrast Media Research symposium in Oslo, Norway.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE Hlthcare Tech Inc put volume heavy and directionally bearish
- GE HealthCare price target raised to $102 from $98 at Evercore ISI
- GE HealthCare price target raised to $102 from $100 at Stifel
- GE HealthCare announces FDA approval of Flyrcado injection PET radiotracer
- Buy/Sell: Wall Street’s top 10 stock calls this week
